Resvida (Resveratrol)

Resvida is a standardized resveratrol supplement derived primarily from Japanese knotweed (Polygonum cuspidatum) or grape skin, where resveratrol acts as a polyphenolic stilbene that activates sirtuin-1 (SIRT1) deacetylase and inhibits cyclooxygenase enzymes to produce antioxidant and anti-inflammatory effects. It is studied for cardiovascular protection, longevity signaling, and endothelial function via upregulation of nitric oxide synthase (eNOS) and suppression of NF-κB inflammatory pathways.

Origin & History

Resvida is a branded, high-purity form of trans-resveratrol (>99% w/w), produced synthetically via a Wittig reaction followed by dealkylation and crystallization. Resveratrol is a stilbenoid polyphenol naturally found in grape skins, berries, and Japanese knotweed, produced by plants as a defense compound.

Historical & Cultural Context

Resveratrol from Japanese knotweed (Polygonum cuspidatum) roots has a history of consumption in food, implying traditional use. It occurs naturally in grape skins and berries, though specific traditional medicinal systems or historical indications are not detailed in the research.

Health Benefits

• Antioxidant activity - resveratrol acts as a dietary antioxidant supplement (evidence quality not specified in available research)
• Anti-inflammatory effects - exhibits cyclooxygenase inhibitory activity (evidence quality not specified in available research)
• Cardiovascular support - investigated for roles in complex biological processes (specific evidence not provided in research)
• Limited clinical evidence available - the research dossier lacks specific human trial data for health outcomes
• Further research needed - no meta-analyses or RCTs with specific outcomes are cited in the available research

How It Works

Resveratrol activates SIRT1, a NAD+-dependent deacetylase that modulates mitochondrial biogenesis via PGC-1α and downregulates inflammatory gene expression through deacetylation of NF-κB subunit p65. It inhibits cyclooxygenase-1 (COX-1) and COX-2 enzymes, reducing prostaglandin E2 synthesis and attenuating the inflammatory cascade at the arachidonic acid pathway. Additionally, resveratrol upregulates endothelial nitric oxide synthase (eNOS), increasing nitric oxide bioavailability, which promotes vasodilation and inhibits platelet aggregation relevant to cardiovascular health.

Scientific Research

The research dossier does not provide specific clinical trials, meta-analyses, or PubMed PMIDs for resveratrol or Resvida. General references note investigation into resveratrol's biological roles and antioxidant properties, but no trial data with study design, sample sizes, or outcomes are included.

Clinical Summary

Human clinical trials on resveratrol have produced mixed results, with many studies limited by small sample sizes (typically 20–100 participants) and varying bioavailability of the compound. A 2013 randomized controlled trial in obese men (n=11) published in Cell Metabolism showed resveratrol (150 mg/day) mimicked caloric restriction by improving mitochondrial function and reducing blood pressure, though larger replication trials have not consistently confirmed these findings. Studies on cardiovascular biomarkers suggest modest reductions in LDL oxidation and improvements in flow-mediated dilation at doses of 150–500 mg/day, but effect sizes are generally small and not all trials reach statistical significance. Overall, the evidence base is promising but preliminary, with researchers calling for larger, longer-duration RCTs before firm efficacy conclusions can be drawn.

Nutritional Profile

Resvida is a proprietary high-purity trans-resveratrol ingredient (typically >99% pure trans-resveratrol) manufactured by DSM. Active compound: trans-3,5,4'-trihydroxystilbene (resveratrol), a polyphenolic stilbenoid. Typical dosing in supplements ranges from 75–500 mg/day of trans-resveratrol. Contains no significant macronutrients (negligible protein, fat, carbohydrate, and fiber at supplement doses). No meaningful vitamin or mineral content. Key bioactive properties: polyphenol with a 4'-hydroxystilbene backbone responsible for antioxidant electron-donating capacity. Bioavailability notes: oral trans-resveratrol is rapidly absorbed (peak plasma levels within ~30–60 minutes) but undergoes extensive first-pass metabolism in the intestine and liver, yielding primary metabolites resveratrol-3-O-glucuronide and resveratrol-3-O-sulfate; free (unconjugated) resveratrol bioavailability is estimated at <1–5% of the ingested dose. Plasma half-life of free resveratrol is approximately 1–3 hours. Metabolites (glucuronides and sulfates) circulate at concentrations 5–10× higher than the parent compound and may retain partial biological activity. Co-administration with dietary fat or quercetin has been suggested to modestly improve bioavailability by inhibiting Phase II conjugation enzymes (SULT1A1, UGT). Resvida's high-purity crystalline trans-resveratrol form is designed to offer more consistent absorption compared to plant-extract-based resveratrol sources, which may contain variable ratios of cis/trans isomers and other grape-derived polyphenols. No calories of nutritional significance per serving.

Preparation & Dosage

No clinically studied dosage ranges or standardization details from human trials are specified in the available research. Resvida is described as >99% trans-resveratrol with 24-month stability when unopened, but dosing information is not provided. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Quercetin, Grape seed extract, Green tea extract, Vitamin C, CoQ10

Safety & Interactions

Resveratrol is generally well tolerated at doses up to 500 mg/day, with higher doses (2–5 g/day) associated with gastrointestinal side effects including nausea, diarrhea, and abdominal discomfort. It inhibits cytochrome P450 enzymes CYP3A4 and CYP2C9, which may elevate plasma concentrations of drugs metabolized by these pathways, including warfarin, statins, and certain calcium channel blockers, raising bleeding or toxicity risk. Resveratrol exhibits mild estrogenic activity via estrogen receptor-beta (ERβ) agonism, making it potentially contraindicated in estrogen-sensitive conditions such as breast, uterine, or ovarian cancers. Safety data during pregnancy and lactation is insufficient, and use should be avoided in these populations until more evidence is available.